AU2006238855B2 - Reagents that bind CCX-CKR2 - Google Patents

Reagents that bind CCX-CKR2 Download PDF

Info

Publication number
AU2006238855B2
AU2006238855B2 AU2006238855A AU2006238855A AU2006238855B2 AU 2006238855 B2 AU2006238855 B2 AU 2006238855B2 AU 2006238855 A AU2006238855 A AU 2006238855A AU 2006238855 A AU2006238855 A AU 2006238855A AU 2006238855 B2 AU2006238855 B2 AU 2006238855B2
Authority
AU
Australia
Prior art keywords
seq
antibody
ccx
ckr2
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006238855A
Other languages
English (en)
Other versions
AU2006238855A1 (en
Inventor
Maureen Howard
Thomas Schall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2006238855A1 publication Critical patent/AU2006238855A1/en
Application granted granted Critical
Publication of AU2006238855B2 publication Critical patent/AU2006238855B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
AU2006238855A 2005-04-21 2006-04-19 Reagents that bind CCX-CKR2 Active AU2006238855B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67414005P 2005-04-21 2005-04-21
US60/674,140 2005-04-21
PCT/US2006/015492 WO2006116319A2 (en) 2005-04-21 2006-04-19 Reagents that bind ccx-ckr2

Publications (2)

Publication Number Publication Date
AU2006238855A1 AU2006238855A1 (en) 2006-11-02
AU2006238855B2 true AU2006238855B2 (en) 2011-12-22

Family

ID=37215373

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006238855A Active AU2006238855B2 (en) 2005-04-21 2006-04-19 Reagents that bind CCX-CKR2

Country Status (14)

Country Link
US (2) US7678891B2 (enExample)
EP (1) EP1871804B1 (enExample)
JP (1) JP4963701B2 (enExample)
KR (1) KR101289567B1 (enExample)
CN (1) CN101163718B (enExample)
AU (1) AU2006238855B2 (enExample)
CA (1) CA2606222C (enExample)
DK (1) DK1871804T3 (enExample)
ES (1) ES2434852T3 (enExample)
IL (1) IL186509A (enExample)
MX (1) MX2007013108A (enExample)
PL (1) PL1871804T3 (enExample)
PT (1) PT1871804E (enExample)
WO (1) WO2006116319A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2012130874A1 (en) 2011-03-28 2012-10-04 Ablynx Nv Bispecific anti-cxcr7 immunoglobulin single variable domains
JP6034023B2 (ja) 2008-05-16 2016-11-30 アブリンクス エン．ヴェー． Ｃｘｃｒ４及び他のｇｐｃｒに指向性を有するアミノ酸配列及びそれを含む化合物
EP2399934B1 (en) * 2009-02-20 2017-09-06 The University of Tokyo Novel monoclonal antibody, and use thereof
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US12448373B2 (en) 2021-04-19 2025-10-21 Amgen Inc. Azetidinyl-acetamides as CXCR7 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170634A1 (en) * 2001-11-30 2004-09-02 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2004099781A2 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)
US20050074826A1 (en) * 2001-11-30 2005-04-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US6537764B1 (en) 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE69737656T2 (de) 1996-09-10 2008-01-03 Theodor Kocher Institut Cxcr3 chemokine rezeptor, antikoerper, nukleinsaeure und deren verfahren zur anwendung
US6140064A (en) * 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
US5876946A (en) * 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
EP0897980A3 (en) 1997-08-20 2002-04-17 Smithkline Beecham Corporation CXCR4B: A human splice variant of CXCR4 chemokine receptor
CA2242308A1 (en) * 1997-12-08 1999-06-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
US6306653B1 (en) * 1998-01-20 2001-10-23 Codon Diagnostics, Llc Detection and treatment of breast disease
CA2320144A1 (en) 1998-02-10 1999-08-12 Millennium Pharmaceuticals, Inc. Neokine protein and nucleic acid molecules and uses therefor
NZ507161A (en) 1998-03-30 2003-12-19 Northwest Biotherapeutics Inc Theraupeutic and diagonistic applications based on the role of the CXCR-4 gene in tumorigenesis
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
US6329510B1 (en) * 1999-01-29 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-CCR1 antibodies and methods of use therefor
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US6365356B1 (en) * 1999-03-17 2002-04-02 Cornell Research Foundation, Inc. Receptors that regulate cell signaling relating to chemokines
CA2367173A1 (en) * 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US20020061599A1 (en) * 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
CA2399593A1 (en) * 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
US20020064770A1 (en) * 2000-03-21 2002-05-30 Nestor John J. Binding compounds and methods for identifying binding compounds
AU2001271502A1 (en) * 2000-06-26 2002-01-08 Gpc Biotech Ag Methods and compositions for isolating biologically active antibodies
CA2511242C (en) * 2002-12-20 2010-01-12 Anita Melikian Inhibitors of human tumor-expressed ccxckr2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170634A1 (en) * 2001-11-30 2004-09-02 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20050074826A1 (en) * 2001-11-30 2005-04-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2004099781A2 (en) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1)

Also Published As

Publication number Publication date
PL1871804T3 (pl) 2014-01-31
EP1871804A4 (en) 2010-01-06
CA2606222C (en) 2015-06-23
WO2006116319A3 (en) 2007-01-04
ES2434852T3 (es) 2013-12-17
AU2006238855A1 (en) 2006-11-02
CN101163718B (zh) 2012-10-10
US7678891B2 (en) 2010-03-16
US20060257410A1 (en) 2006-11-16
KR101289567B1 (ko) 2013-07-24
EP1871804A2 (en) 2008-01-02
IL186509A (en) 2012-04-30
CN101163718A (zh) 2008-04-16
HK1118558A1 (en) 2009-02-13
MX2007013108A (es) 2008-04-07
CA2606222A1 (en) 2006-11-02
JP4963701B2 (ja) 2012-06-27
WO2006116319A2 (en) 2006-11-02
JP2008538508A (ja) 2008-10-30
PT1871804E (pt) 2013-10-31
IL186509A0 (en) 2008-01-20
EP1871804B1 (en) 2013-08-28
DK1871804T3 (da) 2013-12-02
US20100278820A1 (en) 2010-11-04
KR20070122556A (ko) 2007-12-31

Similar Documents

Publication Publication Date Title
AU2007313274B2 (en) Antibodies that bind CXCR7 epitopes
Burns et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development
US20100278820A1 (en) Reagents that bind ccx-ckr2
US7777009B2 (en) Compositions for detecting and treating diseases and conditions related to chemokine receptors
CN101506239A (zh) 抗人α9整联蛋白抗体及其用途
US9587024B2 (en) Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
JP2025020209A (ja) インターロイキン－１９を標的とする化合物および方法
HK1118558B (en) Reagents that bind ccx-ckr2
HK1137356A (en) Antibodies that bind cxcr7 epitopes
JP2003517810A (ja) 抗−ｃｃｒ１抗体およびその使用方法
CN101528257A (zh) 结合cxcr7表位的抗体

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)